Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): A review

Biochemical Pharmacology

Volumn 92, Issue 1, 2014, Pages 73-89

  Wang, Limei ^a   Waltenberger, Birgit ^b   Pferschy Wenzig, Eva Maria ^c   Blunder, Martina ^c   Liu, Xin ^c   Malainer, Clemens ^a   Blazevic, Tina ^a   Schwaiger, Stefan ^b   Rollinger, Judith M ^b   Heiss, Elke H ^a   Schuster, Daniela ^b   Kopp, Brigitte ^a   Bauer, Rudolf ^c   Stuppner, Hermann ^b   Dirsch, Verena M ^a   Atanasov, Atanas G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Diabetes; Natural product; Nuclear receptor; Nutrition; PPAR gamma

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOCHANIN A; CARNOSIC ACID; CARNOSOL; CATECHIN; FALCARINDIOL; FATTY ACID; FLAVONOID; GENISTEIN; GINSENOSIDE RB 1; HONOKIOL; KAEMPFEROL; LINOLEIC ACID; LUTEOLIN; MAGNOLOL; NATURAL PRODUCT; NEOLIGNAN; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLANT EXTRACT; POLYACETYLENE DERIVATIVE; QUERCETIN; QUINONE DERIVATIVE; RESVERATROL; RETINOID X RECEPTOR; SESQUITERPENE LACTONE; STILBENE DERIVATIVE; UNINDEXED DRUG; BIOLOGICAL PRODUCT; PROTEIN BINDING;

ADIPOCYTE; ARTICLE; DIET SUPPLEMENTATION; DRUG BINDING; DRUG RECEPTOR BINDING; ENERGY BALANCE; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; MEDICINAL PLANT; METABOLIC PARAMETERS; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REPORTER GENE; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; AGONISTS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM;

BIOLOGICAL PRODUCTS; ENERGY METABOLISM; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PPAR GAMMA; PROTEIN BINDING;

EID: 84908265684     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.07.018     Document Type: Article

References (254)

1. E.S. Ford, C. Li, and G. Zhao Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US J Diabetes 2 2010 180 193
2. A. Friend, L. Craig, and S. Turner The prevalence of metabolic syndrome in children: a systematic review of the literature Metab Syndr Relat Disord 11 2013 71 80
3. S.M. Grundy, H.B. Brewer Jr., J.I. Cleeman, S.C. Smith Jr., and C. Lenfant Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
4. N. Ouchi, J.L. Parker, J.J. Lugus, and K. Walsh Adipokines in inflammation and metabolic disease Nat Rev Immunol 11 2011 85 97
5. D.F. Berenson, A.R. Weiss, Z.L. Wan, and M.A. Weiss Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering Ann NY Acad Sci 1243 2011 E40 E54
6. C.S. Mizuno, A.G. Chittiboyina, T.W. Kurtz, and H.A. Pershadsingh Avery MA. Type 2 diabetes and oral antihyperglycemic drugs Curr Med Chem 15 2008 61 74
7. S. Seino, H. Takahashi, T. Takahashi, and T. Shibasaki Treating diabetes today: a matter of selectivity of sulphonylureas Diabetes Obes Metab 14 Suppl 1 2012 9 13
8. R.G. Baker, M.S. Hayden, and S. Ghosh NF-kappaB, inflammation, and metabolic disease Cell Metab 13 2011 11 22
9. R.J. Roth Flach, and A.M. Bennett Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease Expert Opin Ther Targets 14 2010 1323 1332
10. M. Furuhashi, and G.S. Hotamisligil Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets Nat Rev Drug Discovery 7 2008 489 503
11. S.J. Wakil, and L.A. Abu-Elheiga Fatty acid metabolism: target for metabolic syndrome J Lipid Res 50 Suppl 2009 S138 S143
12. Y. Cao Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases Nat Rev Drug Discovery 9 2010 107 115
13. J.P. Berger, T.E. Akiyama, and P.T. Meinke PPARs: therapeutic targets for metabolic disease Trends Pharmacol Sci 26 2005 244 251
14. F.A. Monsalve, R.D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases Mediators Inflamm 2013 2013 549627
15. V. Laudet, C. Hanni, J. Coll, F. Catzeflis, and D. Stehelin Evolution of the nuclear receptor gene superfamily EMBO J 11 1992 1003 1013
16. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
17. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 1992 879 887
18. B.M. Forman, J. Chen, and R.M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta Proc Natl Acad Sci USA 94 1997 4312 4317
19. I. Dussault, and B.M. Forman Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors Prostaglandins Other Lipid Mediat 62 2000 1 13
20. R.M. Evans, G.D. Barish, and Y.X. Wang PPARs and the complex journey to obesity Nat Med 10 2004 355 361
21. K.L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J.A. Gustafsson Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor Proc Natl Acad Sci USA 90 1993 1440 1444
22. T. Lemberger, B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology Ann Rev Cell Dev Biol 12 1996 335 363
23. S. Yu, and J.K. Reddy Transcription coactivators for peroxisome proliferator-activated receptors Biochim Biophys Acta 1771 2007 936 951
24. J.N. Feige, and J. Auwerx Transcriptional coregulators in the control of energy homeostasis Trends Cell Biol 17 2007 292 301
25. D. Auboeuf, J. Rieusset, L. Fajas, P. Vallier, V. Frering, and J.P. Riou Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients Diabetes 46 1997 1319 1327
26. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 1999 649 688
27. J.C. Fruchart Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease Atherosclerosis 205 2009 1 8
28. G.D. Barish, V.A. Narkar, and R.M. Evans PPAR delta: a dagger in the heart of the metabolic syndrome J Clin Invest 116 2006 590 597
29. U. Seedorf, and J. Aberle Emerging roles of PPARdelta in metabolism Biochim Biophys Acta 1771 2007 1125 1131
30. Y. Zhu, C. Qi, J.R. Korenberg, X.N. Chen, D. Noya, and M.S. Rao Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms Proc Natl Acad Sci USA 92 1995 7921 7925
31. L. Fajas, D. Auboeuf, E. Raspe, K. Schoonjans, A.M. Lefebvre, and R. Saladin The organization, promoter analysis, and expression of the human PPARgamma gene J Biol Chem 272 1997 18779 18789
32. A. Werman, A. Hollenberg, G. Solanes, C. Bjorbaek, A.J. Vidal-Puig, and J.S. Flier Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin J Biol Chem 272 1997 20230 20235
33. A.J. Vidal-Puig, R.V. Considine, M. Jimenez-Linan, A. Werman, W.J. Pories, and J.F. Caro Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids J Clin Invest 99 1997 2416 2422
34. G. Medina-Gomez, S.L. Gray, L. Yetukuri, K. Shimomura, S. Virtue, and M. Campbell PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genet 3 2007 e64
35. S.A. Kliewer, S.S. Sundseth, S.A. Jones, P.J. Brown, G.B. Wisely, and C.S. Koble Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Proc Natl Acad Sci USA 94 1997 4318 4323
36. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Bio Chem 270 1995 12953 12956
37. N. Cho, and Y. Momose Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress Curr Top Med Chem 8 2008 1483 1507
38. I. Tzameli, H. Fang, M. Ollero, H. Shi, J.K. Hamm, and P. Kievit Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes J Biol Chem 279 2004 36093 36102
39. M. Lehrke, and M.A. Lazar The many faces of PPARgamma Cell 123 2005 993 999
40. P.A. Subramani, M.C. Reddy, and V.R. Narala The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands Endocr Metab Imm Disorders Drug Targets 13 2013 175 183
41. T. Goto, H. Nagai, K. Egawa, Y.I. Kim, S. Kato, and A. Taimatsu Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARgamma agonist Biochem J 438 2011 111 119
42. F.J. Schopfer, M.P. Cole, A.L. Groeger, C.S. Chen, N.K. Khoo, and S.R. Woodcock Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions J Biol Chem 285 2010 12321 12333
43. T. Itoh, L. Fairall, K. Amin, Y. Inaba, A. Szanto, and B.L. Balint Structural basis for the activation of PPARgamma by oxidized fatty acids Nat Struct Mol Biol 15 2008 924 931
44. P. Tontonoz, and B.M. Spiegelman Fat and beyond: the diverse biology of PPARgamma Annu Rev Biochem 77 2008 289 312
45. H.K. Na, and Y.J. Surh Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation Biochem Pharmacol 66 2003 1381 1391
46. S. Heikkinen, J. Auwerx, and C.A. Argmann PPARgamma in human and mouse physiology Biochim Biophys Acta 1771 2007 999 1013
47. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes Dev 8 1994 1224 1234
48. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 1994 1147 1156
49. I.B. Sears, M.A. MacGinnitie, L.G. Kovacs, and R.A. Graves Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma Mol Cell Biol 16 1996 3410 3419
50. Y. Barak, M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, and K.R. Chien PPAR gamma is required for placental, cardiac, and adipose tissue development Mol Cell 4 1999 585 595
51. J. Auwerx PPARgamma, the ultimate thrifty gene Diabetologia 42 1999 1033 1049
52. C. Christodoulides, and A. Vidal-Puig PPARs and adipocyte function Mol Cell Endocrinol 318 2010 61 68
53. F. Picard, and J. Auwerx PPAR(gamma) and glucose homeostasis Ann Rev Nutr 22 2002 167 197
54. M. Ahmadian, J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, and M. Downes PPARgamma signaling and metabolism: the good, the bad and the future Nat Med 19 2013 557 566
55. I. Szatmari, E. Rajnavolgyi, and L. Nagy PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function Ann NY Acad Sci 1088 2006 207 218
56. L. Szeles, D. Torocsik, and L. Nagy PPARgamma in immunity and inflammation: cell types and diseases Biochim Biophys Acta 1771 2007 1014 1030
57. W. Huang, and C.K. Glass Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance Arterioscl Throm Vas Biol 30 2010 1542 1549
58. C.K. Glass, and K. Saijo Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells Nat Rev Immunol 10 2010 365 376
59. L. Zhang, and A. Chawla Role of PPARgamma in macrophage biology and atherosclerosis Trends Endocrinol Metabol: TEM 15 2004 500 505
60. S. Han, and J. Roman Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics Anticancer Drugs 18 2007 237 244
61. A.K. Reka, H. Kurapati, V.R. Narala, G. Bommer, J. Chen, and T.J. Standiford Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition Mol Cancer Ther 9 2010 3221 3232
62. J.H. Choi, A.S. Banks, J.L. Estall, S. Kajimura, P. Bostrom, and D. Laznik Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 Nature 466 2010 451 456
63. S.M. Rangwala, B. Rhoades, J.S. Shapiro, A.S. Rich, J.K. Kim, and G.I. Shulman Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity Dev Cell 5 2003 657 663
64. M.L. Fitzgerald, K.J. Moore, and M.W. Freeman Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home J Mol Med (Berl) 80 2002 271 281
65. J.C. Fruchart, B. Staels, and P. Duriez PPARS, metabolic disease and atherosclerosis Pharmacol Res 44 2001 345 352
66. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscl Thromb Vas Biol 30 2010 894 899
67. F.M. Martens, F.L. Visseren, J. Lemay, E.J. de Koning, and T.J. Rabelink Metabolic and additional vascular effects of thiazolidinediones Drugs 62 2002 1463 1480
68. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone New England J Med 331 1994 1188 1193
69. S. Kumar, A.J. Boulton, H. Beck-Nielsen, F. Berthezene, M. Muggeo, and B. Persson Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group Diabetologia 39 1996 701 709
70. Y. Iwamoto, K. Kosaka, T. Kuzuya, Y. Akanuma, Y. Shigeta, and T. Kaneko Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19 1996 151 156
71. M.K. Cavaghan, D.A. Ehrmann, M.M. Byrne, and K.S. Polonsky Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance J Clin Invest 100 1997 530 537
72. S. Schwartz, P. Raskin, V. Fonseca, and J.F. Graveline Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group New England J Med 338 1998 861 866
73. D.G. Maggs, T.A. Buchanan, C.F. Burant, G. Cline, B. Gumbiner, and W.A. Hsueh Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial Ann Internal Med 128 1998 176 185
74. C.J. Tack, M.K. Ong, J.A. Lutterman, and P. Smits Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone Diabetologia 41 1998 569 576
75. S. Kumar, A. Prange, J. Schulze, S. Lettis, and A.H. Barnett Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients Diabet Med 15 1998 772 779
76. J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 83 1998 1818 1820
77. T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, and K. Masuo Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives Am J Hypertension 8 1995 316 320
78. M.N. Ghazzi, J.E. Perez, T.K. Antonucci, J.H. Driscoll, S.M. Huang, and B.W. Faja Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group Diabetes 46 1997 433 439
79. P.B. Watkins, and R.W. Whitcomb Hepatic dysfunction associated with troglitazone New England J Med 338 1998 916 917
80. J. Kohlroser, J. Mathai, J. Reichheld, B.F. Banner, and H.L. Bonkovsky Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration Am J Gastroenterol 95 2000 272 276
81. B.A. Neuschwander-Tetri, W.L. Isley, J.C. Oki, S. Ramrakhiani, S.G. Quiason, and N.J. Phillips Troglitazone-induced hepatic failure leading to liver transplantation. A case report Ann Internal Med 129 1998 38 41
82. N. Gitlin, N.L. Julie, C.L. Spurr, K.N. Lim, and H.M. Juarbe Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone Ann Internal Med 129 1998 36 38
83. A. Shibuya, M. Watanabe, Y. Fujita, K. Saigenji, S. Kuwao, and H. Takahashi An autopsy case of troglitazone-induced fulminant hepatitis Diabetes Care 21 1998 2140 2143
84. E.J. Murphy, T.J. Davern, A.O. Shakil, L. Shick, U. Masharani, and H. Chow Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group Dig Dis Sci 45 2000 549 553
85. D.J. Graham, L. Green, J.R. Senior, and P. Nourjah Troglitazone-induced liver failure: a case study Am J Med 114 2003 299 306
86. H.E. Lebovitz, J.F. Dole, R. Patwardhan, E.B. Rappaport, and M.I. Freed Rosiglitazone monotherapy is effective in patients with type 2 diabetes J Clin Endocrinol Metabol 86 2001 280 288
87. P. Raskin, M. Rendell, M.C. Riddle, J.F. Dole, M.I. Freed, and J. Rosenstock A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes Diabetes Care 24 2001 1226 1232
88. L.S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E.B. Rappaport, and A. Salzman Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes Diabetes Care 24 2001 308 315
89. A.B. Mayerson, R.S. Hundal, S. Dufour, V. Lebon, D. Befroy, and G.W. Cline The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 51 2002 797 802
90. A. Raji, E.W. Seely, S.A. Bekins, G.H. Williams, and D.C. Simonson Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients Diabetes Care 26 2003 172 178
91. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes New England J Med 356 2007 2457 2471
92. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
93. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, and N.P. Jones Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis New England J Med 357 2007 28 38
94. P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, and M. Hanefeld Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
95. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Internal Med 170 2010 1191 1201
96. J. Al-Salman, H. Arjomand, D.G. Kemp, and M. Mittal Hepatocellular injury in a patient receiving rosiglitazone. A case report Ann Int Med 132 2000 121 124
97. L.M. Forman, D.A. Simmons, and R.H. Diamond Hepatic failure in a patient taking rosiglitazone Ann Internal Med 132 2000 118 121
98. S. Fullert, F. Schneider, E. Haak, H. Rau, K. Badenhoop, and G. Lubben Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study J Clin Endocrinol Metab 87 2002 5503 5506
99. R.B. Goldberg, D.M. Kendall, M.A. Deeg, J.B. Buse, A.J. Zagar, and J.A. Pinaire A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554
100. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, and I.K. Moules Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
101. S.E. Nissen, S.J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, and A. Perez Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
102. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, and C. Worrall Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 304 2010 411 418
103. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study, The Pioglitazone 001 Study Group Diabetes Care 23 2000 1605 1611
104. B. Cariou, B. Charbonnel, and B. Staels Thiazolidinediones and PPARgamma agonists: time for a reassessment Trends Endocrinol Metab: TEM 23 2012 205 215
105. T. Bongartz, B. Coras, T. Vogt, J. Scholmerich, and U. Muller-Ladner Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study Rheumatology (Oxford) 44 2005 126 129
106. H. Hirose, T. Kawai, Y. Yamamoto, M. Taniyama, M. Tomita, and K. Matsubara Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes Metab: Clin Exp 51 2002 314 317
107. P. Balakumar, and S. Kathuria Submaximal PPARgamma activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders Brit J Pharmacol 166 2012 1981 1992
108. M. Schupp, M. Clemenz, R. Gineste, H. Witt, J. Janke, and S. Helleboid Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 54 2005 3442 3452
109. L.S. Higgins, and A.M. Depaoli Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation Am J Clin Nut 91 2010 72S 267S
110. K. Bhalla, B.J. Hwang, J.H. Choi, R. Dewi, L. Ou, and J. McLenithan N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor gamma ligand with partial and full agonist activity in vitro and in vivo J Biol Chem 286 2011 41626 41635
111. M. Heald, and M.A. Cawthorne Dual acting and pan-PPAR activators as potential anti-diabetic therapies Handb Exp Pharmacol 2011 35 51
112. A. Tenenbaum, M. Motro, and E.Z. Fisman Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons Cardiovasc Diabetol 4 2005 14
113. A. Tenenbaum, and E.Z. Fisman Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol 11 2012 140
114. C. Knouff, and J. Auwerx Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology Endocr Rev 25 2004 899 918
115. J.A. Beutler Natural products as a foundation for drug discovery Curr Protoc Pharmacol 2009 Chapter 9:Unit 9 11
116. G.M. Cragg, and D.J. Newman Natural products: a continuing source of novel drug leads Biochim Biophys Acta 1830 2013 3670 3695
117. C.J. Henrich, and J.A. Beutler Matching the power of high throughput screening to the chemical diversity of natural products Nat Prod Rep 30 2013 1284 1298
118. J. Clardy, and C. Walsh Lessons from natural molecules Nature 432 2004 829 837
119. P. Ertl, S. Roggo, and A. Schuffenhauer Natural product-likeness score and its application for prioritization of compound libraries J Chem Inf Model 48 2008 68 74
120. N.R. Farnsworth, O. Akerele, A.S. Bingel, D.D. Soejarto, and Z. Guo Medicinal plants in therapy Bull World Health Organ 63 1985 965 981
121. M. Mueller, and A. Jungbauer Red clover extract: a putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome Menopause 15 2008 1120 1131
122. S. Vogl, P. Picker, J. Mihaly-Bison, N. Fakhrudin, A.G. Atanasov, and E.H. Heiss Ethnopharmacological in vitro studies on Austria's folk medicine - an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs J Ethnopharmacol 149 2013 750 771
123. Local Food-Nutraceuticals Consortium Understanding local Mediterranean diets: a multidisciplinary pharmacological and ethnobotanical approach Pharmacol Res 52 2005 353 366
124. K.B. Christensen, A. Minet, H. Svenstrup, K. Grevsen, H. Zhang, and E. Schrader Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake Phytother Res 23 2009 1316 1325
125. M.H. Yang, B. Avula, T. Smillie, I.A. Khan, and S.I. Khan Screening of medicinal plants for PPARalpha and PPARgamma activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis Planta Medica 79 2013 1084 1095
126. A. Benhaddou-Andaloussi, L.C. Martineau, D. Vallerand, Y. Haddad, A. Afshar, and A. Settaf Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells Diabetes Obes Metab 12 2010 148 157
127. M. Mueller, and A. Jungbauer Culinary plants, herbs and spices-A rich source of PPARγ ligands Food Chem 117 2009 660 667
128. L.W. Xie, A.G. Atanasov, D.A. Guo, C. Malainer, J.X. Zhang, and M. Zehl Activity-guided isolation of NF-kappaB inhibitors and PPARgamma agonists from the root bark of Lycium chinense Miller J Ethnopharmacol 152 2014 470 477
129. S. Vogl, A.G. Atanasov, M. Binder, M. Bulusu, M. Zehl, and N. Fakhrudin The Herbal Drug Melampyrum pratense L. (Koch): Isolation and Identification of Its Bioactive Compounds Targeting Mediators of Inflammation Evid Based Complement Alternat Med 2013 2013 395316
130. E. Rozema, A.G. Atanasov, N. Fakhrudin, J. Singhuber, U. Namduang, and E.H. Heiss Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-kappaB, PPARalpha and PPARgamma and the Respective Bioactive Compounds Evid Based Complement Alternat Med 2012 2012 983023
131. R.K. Petersen, K.B. Christensen, A.N. Assimopoulou, X. Frette, V.P. Papageorgiou, and K. Kristiansen Pharmacophore-driven identification of PPARgamma agonists from natural sources J Comput-Aid Mol Des 25 2011 107 116
132. K.B. Christensen, M. Jorgensen, D. Kotowska, R.K. Petersen, K. Kristiansen, and L.P. Christensen Activation of the nuclear receptor PPARgamma by metabolites isolated from sage (Salvia officinalis L.) J Ethnopharmacol 132 2010 127 133
133. K.B. Christensen, R.K. Petersen, K. Kristiansen, and L.P. Christensen Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma Phytother Res 24 Suppl 2 2010 S129 S132
134. X.K. Fang, J. Gao, and D.N. Zhu Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity Life Sci 82 2008 615 622
135. Z.C. Dang, V. Audinot, S.E. Papapoulos, J.A. Boutin, and C.W. Lowik Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein J Biol Chem 278 2003 962 967
136. M. Kuroda, Y. Mimaki, Y. Sashida, T. Mae, H. Kishida, and T. Nishiyama Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice Bioorg Med Chem Lett 13 2003 4267 4272
137. M. Mueller, B. Lukas, J. Novak, T. Simoncini, A.R. Genazzani, and A. Jungbauer Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists J Agr Food Chem 56 2008 11621 11630
138. P. Shen, M.H. Liu, T.Y. Ng, Y.H. Chan, and E.L. Yong Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro J Nutr 136 2006 899 905
139. M. Rupp, T. Schroeter, R. Steri, H. Zettl, E. Proschak, and K. Hansen From machine learning to natural product derivatives that selectively activate transcription factor PPARgamma ChemMedChem 5 2010 191 194
140. N. Fakhrudin, A. Ladurner, A.G. Atanasov, E.H. Heiss, L. Baumgartner, and P. Markt Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma Mol Pharmacol 77 2010 559 566
141. S.N. Lewis, L. Brannan, A.J. Guri, P. Lu, R. Hontecillas, and J. Bassaganya-Riera Dietary alpha-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-gamma PLoS One 6 2011 e24031
142. N.K. Salam, T.H. Huang, B.P. Kota, M.S. Kim, Y. Li, and D.E. Hibbs Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study Chem Biol Drug Des 71 2008 57 70
143. Y. Tanrikulu, O. Rau, O. Schwarz, E. Proschak, K. Siems, and L. Muller-Kuhrt Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists Chembiochem 10 2009 75 78
144. T. Waku, T. Shiraki, T. Oyama, Y. Fujimoto, K. Maebara, and N. Kamiya Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids J Mol Biol 385 2009 188 199
145. B.P. Kota, T.H. Huang, and B.D. Roufogalis An overview on biological mechanisms of PPARs Pharmacol Res 51 2005 85 94
146. N. Marx, H. Duez, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Circ Res 94 2004 1168 1178
147. T.M. Willson, and W. Wahli Peroxisome proliferator-activated receptor agonists Curr Opin Chem Biol 1 1997 235 241
148. R.M. Touyz, and E.L. Schiffrin Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications Vasc Pharmacol 45 2006 19 28
149. B. Grygiel-Gorniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review Nutr J 13 2014 17
150. L. Michalik, J. Auwerx, J.P. Berger, V.K. Chatterjee, C.K. Glass, and F.J. Gonzalez International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacol Rev 58 2006 726 741
151. S.J. Bensinger, and P. Tontonoz Integration of metabolism and inflammation by lipid-activated nuclear receptors Nature 454 2008 470 477
152. L.S. Doshi, M.K. Brahma, U.A. Bahirat, A.V. Dixit, and K.V. Nemmani Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents Exp Opin Invest Drugs 19 2010 489 512
153. B.G. Shearer, and A.N. Billin The next generation of PPAR drugs: do we have the tools to find them Biochim Biophys Acta 1771 2007 1082 1093
154. D. Zhang, X. Nie, H. Pan, L. Yu, X. Yang, and J. Xu [Study on effect of total saponins from Semen Nigellae on inflammatory mediators and ERK/MAPK pathway in stimulated macrophage] Zhongguo Zhong Yao Za Zhi 35 2010 2594 2598
155. Y.K. Lee, W.S. Lee, J.T. Hwang, D.Y. Kwon, Y.J. Surh, and O.J. Park Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells J Agr Food Chem 57 2009 305 310
156. T. Saito, D. Abe, and K. Sekiya Sakuranetin induces adipogenesis of 3T3-L1 cells through enhanced expression of PPARgamma2 Biochem Biophys Res Commun 372 2008 835 839
157. T.H. Huang, G. Peng, B.P. Kota, G.Q. Li, J. Yamahara, and B.D. Roufogalis Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component Toxicol Appl Pharmacol 207 2005 160 169
158. Y.T. Li, L. Li, J. Chen, T.C. Hu, J. Huang, and Y.W. Guo 7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation Acta Pharmacol Sin 30 2009 1351 1358
159. J.T. Hwang, M.S. Lee, H.J. Kim, M.J. Sung, H.Y. Kim, and M.S. Kim Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways Phytother Res 23 2009 262 266
160. J. Lee, E. Jung, S. Kim, S. Huh, Y. Kim, and S.Y. Byun Isorhamnetin represses adipogenesis in 3T3-L1 cells Obesity (Silver Spring) 17 2009 226 232
161. Z. Gong, C. Huang, X. Sheng, Y. Zhang, Q. Li, and M.W. Wang The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism Endocrinology 150 2009 104 113
162. A. Jacob, R. Wu, M. Zhou, and P. Wang Mechanism of the anti-inflammatory effect of Curcumin: PPAR-gamma Activation PPAR Res 2007 2007 89369
163. A.M. Siddiqui, X. Cui, R. Wu, W. Dong, M. Zhou, and M. Hu The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma Crit Care Med 34 2006 1874 1882
164. N. Takahashi, T. Kawada, T. Goto, T. Yamamoto, A. Taimatsu, and N. Matsui Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes FEBS Lett 514 2002 315 322
165. S.W. Chung, M.K. Kim, J.H. Chung, D.H. Kim, J.S. Choi, and S. Anton Peroxisome proliferator-activated receptor activation by a short-term feeding of zingerone in aged rats J Med Food 12 2009 345 350
166. J.Y. Park, T. Kawada, I.S. Han, B.S. Kim, T. Goto, and N. Takahashi Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism FEBS Lett 572 2004 266 270
167. M. Zhang, C. Deng, J. Zheng, J. Xia, and D. Sheng Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma Int Immunopharmacol 6 2006 1233 1242
168. S.Z. Dong, S.P. Zhao, Z.H. Wu, J. Yang, X.Z. Xie, and B.L. Yu Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway Mol Cell Biochem 358 2011 281 285
169. K. Kuroyanagi, M.S. Kang, T. Goto, S. Hirai, K. Ohyama, and T. Kusudo Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes Biochem Biophys Res Commun 366 2008 219 225
170. S.E. O'Sullivan, E.J. Tarling, A.J. Bennett, D.A. Kendall, and M.D. Randall Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma Biochem Biophys Res Commun 337 2005 824 831
171. H. Waki, K.W. Park, N. Mitro, L. Pei, R. Damoiseaux, and D.C. Wilpitz The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression Cell Metab 5 2007 357 370
172. I.K. Lee, J.H. Lee, and B.S. Yun Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis Bioorg Med Chem Lett 18 2008 4566 4568
173. F.D. Mora, D.K. Jones, P.V. Desai, A. Patny, M.A. Avery, and D.R. Feller Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells J Nat Prod 69 2006 547 552
174. V. Zoete, A. Grosdidier, and O. Michielin Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators Biochim Biophys Acta 1771 2007 915 925
175. A.G. Atanasov, J.N. Wang, S.P. Gu, J. Bu, M.P. Kramer, and L. Baumgartner Honokiol: a non-adipogenic PPARgamma agonist from nature Biochim Biophys Acta 1830 2013 4813 4819
176. E.J. Sohn, C.S. Kim, Y.S. Kim, D.H. Jung, D.S. Jang, and Y.M. Lee Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats Life Sci 80 2007 468 475
177. M.S. Beaudoin, L.A. Snook, A.M. Arkell, J.A. Simpson, G.P. Holloway, and D.C. Wright Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats Am J Physiol Reg I 305 2013 R542 R551
178. G. Alberdi, V.M. Rodriguez, J. Miranda, M.T. Macarulla, N. Arias, and C. Andres-Lacueva Changes in white adipose tissue metabolism induced by resveratrol in rats Nutr Metab 8 2011 29
179. C.C. Chuang, K. Martinez, G. Xie, A. Kennedy, A. Bumrungpert, and A. Overman Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes Am J Clin Nutr 92 2010 1511 1521
180. Z.E. Floyd, Z.Q. Wang, G. Kilroy, and W.T. Cefalu Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol Metab: Clin Exp 57 2008 S32 S38
181. W. Dong, X. Wang, S. Bi, Z. Pan, S. Liu, and H. Yu Inhibitory effects of resveratrol on foam cell formation are mediated through monocyte chemotactic protein-1 and lipid metabolism-related proteins Int J Mol Med 33 2014 1161 1168
182. I. Voloshyna, O. Hai, M.J. Littlefield, S. Carsons, and A.B. Reiss Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine Eur J Pharmacol 698 2013 299 309
183. Y. Zhang, Z. Luo, L. Ma, Q. Xu, Q. Yang, and L. Si Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation Int J Mol Med 25 2010 729 734
184. A. Kennedy, A. Overman, K. Lapoint, R. Hopkins, T. West, and C.C. Chuang Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol J Lipid Res 50 2009 225 232
185. H. Ge, J.F. Zhang, B.S. Guo, Q. He, B.Y. Wang, and B. He Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma Vasc Pharmacol 46 2007 114 121
186. P. Brasnyo, G.A. Molnar, M. Mohas, L. Marko, B. Laczy, and J. Cseh Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients Brit J Nutr 106 2011 383 389
187. C. Weidner, J.C. de Groot, A. Prasad, A. Freiwald, C. Quedenau, and M. Kliem Amorfrutins are potent antidiabetic dietary natural products Proc Natl Acad Sci USA 109 2012 7257 7262
188. C. Weidner, S.J. Wowro, A. Freiwald, K. Kawamoto, A. Witzke, and M. Kliem Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with potent glucose-lowering properties Diabetologia 56 2013 1802 1812
189. W. Lee, J. Ham, H.C. Kwon, Y.K. Kim, and S.N. Kim Anti-diabetic effect of amorphastilbol through PPARalpha/gamma dual activation in db/db mice Biochem Biophys Res Commun 432 2013 73 79
190. H. Kotani, H. Tanabe, H. Mizukami, M. Makishima, and M. Inoue Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor J Nat Prod 73 2010 1332 1336
191. H. Kotani, H. Tanabe, H. Mizukami, S. Amagaya, and M. Inoue A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers Biol Pharmaceut Bull 35 2012 1 9
192. C.G. Jung, H. Horike, B.Y. Cha, K.O. Uhm, R. Yamauchi, and T. Yamaguchi Honokiol increases ABCA1 expression level by activating retinoid X receptor beta Biol Pharmaceut Bull 33 2010 1105 1111
193. H. Zhang, X. Xu, L. Chen, J. Chen, L. Hu, and H. Jiang Molecular determinants of magnolol targeting both RXRalpha and PPARgamma PLoS One 6 2011 e28253
194. S.S. Choi, B.Y. Cha, Y.S. Lee, T. Yonezawa, T. Teruya, and K. Nagai Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells Life Sci 84 2009 908 914
195. A.C. Puhl, A. Bernardes, R.L. Silveira, J. Yuan, J.L. Campos, and D.M. Saidemberg Mode of peroxisome proliferator-activated receptor gamma activation by luteolin Mol Pharmacol 81 2012 788 799
196. R.T. Nolte, G.B. Wisely, S. Westin, J.E. Cobb, M.H. Lambert, and R. Kurokawa Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma Nature 395 1998 137 143
197. J.C. de Groot, C. Weidner, J. Krausze, K. Kawamoto, F.C. Schroeder, and S. Sauer Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor gamma J Med Chem 56 2013 1535 1543
198. L. Guasch, E. Sala, C. Valls, M. Blay, M. Mulero, and L. Arola Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity J Comput-Aid Mol Des 25 2011 717 728
199. M.V. Liberato, A.S. Nascimento, S.D. Ayers, J.Z. Lin, A. Cvoro, and R.L. Silveira Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and pan-PPAR partial agonists PLoS One 7 2012 e36297
200. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, and H. Weissig The Protein Data Bank Nucleic Acids Res 28 2000 235 242
201. J.Y. Cho, P.S. Kim, J. Park, E.S. Yoo, K.U. Baik, and Y.K. Kim Inhibitor of tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa J Ethnopharmacol 70 2000 127 133
202. Gao Xuemin Applied illustrated compendium of materia medica (Chinese-English edition) 2006 Foreign Languages Press
203. C.P. Khare Indian Medicinal Plants: An Illustrated Dictionary 2007 Springer
204. N. Takahashi, T. Goto, A. Taimatsu, K. Egawa, S. Katoh, and T. Kusudo Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation Biochem Biophys Res Commun 390 2009 1372 1376
205. D.W. Shin, S.N. Kim, S.M. Lee, W. Lee, M.J. Song, and S.M. Park (-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation Biochem Pharmacol 77 2009 125 133
206. A. Inta, P. Trisonthi, and C. Trisonthi Analysis of traditional knowledge in medicinal plants used by Yuan in Thailand J Ethnopharmacol 149 2013 344 351
207. N.T. Dat, K. Lee, Y.S. Hong, Y.H. Kim, C.V. Minh, and J.J. Lee A peroxisome proliferator-activated receptor-gamma agonist and other constituents from Chromolaena odorata Planta Medica 75 2009 803 807
208. M.L. Zhang, D. Irwin, X.N. Li, F. Sauriol, X.W. Shi, and Y.F. Wang PPARgamma agonist from Chromolaena odorata J Nat Prod 75 2012 2076 2081
209. H. Yokoi, H. Mizukami, A. Nagatsu, T. Ohno, H. Tanabe, and M. Inoue Peroxisome proliferator-activated receptor gamma ligands isolated from adlay seed (Coix lacryma-jobi L. var. ma-yuen STAPF.) Biol Pharmaceut Bull 32 2009 735 740
210. C.L. Cornick, B.H. Strongitharm, G. Sassano, C. Rawlins, A.E. Mayes, and A.N. Joseph Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice J Nutr Biochem 20 2009 806 815
211. Y.Q. He, G.Y. Ma, J.N. Peng, Z.Y. Ma, and M.T. Hamann Liver X receptor and peroxisome proliferator-activated receptor agonist from Cornus alternifolia Biochim Biophys Acta 1820 2012 1021 1026
212. S.K. Vareed, M.K. Reddy, R.E. Schutzki, and M.G. Nair Anthocyanins in Cornus alternifolia, Cornus controversa, Cornus kousa and Cornus florida fruits with health benefits Life Sci 78 2006 777 784
213. M. Katsukawa, R. Nakata, Y. Takizawa, K. Hori, S. Takahashi, and H. Inoue Citral, a component of lemongrass oil, activates PPARalpha and gamma and suppresses COX-2 expression Biochim Biophys Acta 1801 2010 1214 1220
214. K. Hostettmann [History of a plant: the example of Echinacea] Forsch Komplementarmed Klass Naturheilkd 10 Suppl 1 2003 9 12
215. K.B. Christensen, R.K. Petersen, S. Petersen, K. Kristiansen, and L.P. Christensen Activation of PPARgamma by metabolites from the flowers of purple coneflower (Echinacea purpurea) J Nat Prod 72 2009 933 937
216. S. Sasidharan, R. Nilawatyi, R. Xavier, L.Y. Latha, and R. Amala Wound healing potential of Elaeis guineensis Jacq leaves in an infected albino rat model Molecules 15 2010 3186 3199
217. F. Fang, Z. Kang, and C. Wong Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors Mol Nutr Food Res 54 2010 345 352
218. G. Zou, Z. Gao, J. Wang, Y. Zhang, H. Ding, and J. Huang Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma Biochem Pharmacol 75 2008 1381 1392
219. M.A. Tantry, J.A. Dar, A. Idris, S. Akbar, and A.S. Shawl Acylated flavonol glycosides from Epimedium elatum, a plant endemic to the Western Himalayas Fitoterapia 83 2012 665 670
220. M. Kuroda, Y. Mimaki, S. Honda, H. Tanaka, S. Yokota, and T. Mae Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity Bioorg Med Chem 18 2010 962 970
221. A. Ouarghidi, G.J. Martin, B. Powell, G. Esser, and A. Abbad Botanical identification of medicinal roots collected and traded in Morocco and comparison to the existing literature J Ethnobiol Ethnomed 9 2013 59
222. H.G. Park, E.J. Bak, G.H. Woo, J.M. Kim, Z. Quan, and H.K. Yoon Licochalcone E has an antidiabetic effect J Nutr Biochem 23 2012 759 767
223. Sauvan N, Renimel I, Lamy C, Dupont D. Patent US 7527813 B2: Cosmetic composition containing an extract of Limnocitrus littoralis. Google Patents, 2009.
224. Q.T. Do, C. Lamy, I. Renimel, N. Sauvan, P. Andre, and F. Himbert Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin Planta Medica 73 2007 1235 1240
225. Committee of National Pharmacopoeia China Pharmacopoeia (Part 1) 2010 Chemical Industry Press Beijing
226. N.X. Nhiem, P.H. Yen, N.T. Ngan, T.H. Quang, P.V. Kiem, and C.V. Minh Inhibition of nuclear transcription factor-kappaB and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia J Med Food 15 2012 369 377
227. X. Liu, S. Jiang, K. Xu, H. Sun, Y. Zhou, and X. Xu Quantitative analysis of chemical constituents in different commercial parts of Notopterygium incisum by HPLC-DAD-MS J Ethnopharmacol 126 2009 474 479
228. A.G. Atanasov, M. Blunder, N. Fakhrudin, X. Liu, S.M. Noha, and C. Malainer Polyacetylenes from Notopterygium incisum - new selective partial agonists of peroxisome proliferator-activated receptor-gamma PLoS One 8 2013 e61755
229. K.L. Han, M.H. Jung, J.H. Sohn, and J.K. Hwang Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes Biol Pharmaceut Bull 29 2006 110 113
230. W. Shang, Y. Yang, B. Jiang, H. Jin, L. Zhou, and S. Liu Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARgamma2 and C/EBPalpha gene expression Life Sci 80 2007 618 625
231. V.K. Wong, P. Chiu, S.S. Chung, L.M. Chow, Y.Z. Zhao, and B.B. Yang Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo Clin Cancer Res 11 2005 6002 6011
232. M.S. Jaradat, D.J. Noonan, B. Wu, M.A. Avery, and D.R. Feller Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists Planta Medica 68 2002 667 671
233. K.H. Wong, G.Q. Li, K.M. Li, V. Razmovski-Naumovski, and K. Chan Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases J Ethnopharmacol 134 2011 584 607
234. T. Kim, W. Lee, K.H. Jeong, J.H. Song, S.H. Park, and P. Choi Total synthesis and dual PPARalpha/gamma agonist effects of amorphastilbol and its synthetic derivatives Bioorg Med Chem Lett 22 2012 4122 4126
235. O. Rau, M. Wurglics, A. Paulke, J. Zitzkowski, N. Meindl, and A. Bock Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma Planta Medica 72 2006 881 887
236. M.H. Yu, H.G. Im, J.W. Lee, M.H. Bo, H.J. Kim, and S.K. Kim Effects of ethanol extract from Saururus chinensis (Bour.) Baill on lipid and antioxidant metabolisms in rats fed a high-fat diet Nat Prod Res 22 2008 275 283
237. B.Y. Hwang, J.H. Lee, J.B. Nam, H.S. Kim, Y.S. Hong, and J.J. Lee Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor gamma J Nat Prod 65 2002 616 617
238. E.M. Pferschy-Wenzig, A.G. Atanasov, C. Malainer, S.M. Noha, O. Kunert, and D. Schuster Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma J Nat Prod 77 2014 842 847
239. S.V. Nampoothiri, S.S. Binil Raj, A. Prathapan, P.A. Abhilash, C. Arumughan, and A. Sundaresan In vitro antioxidant activities of the methanol extract and its different solvent fractions obtained from the fruit pericarp of Terminalia bellerica Nat Prod Res 25 2011 277 287
240. M.H. Yang, Y. Vasquez, Z. Ali, I.A. Khan, and S.I. Khan Constituents from Terminalia species increase PPARalpha and PPARgamma levels and stimulate glucose uptake without enhancing adipocyte differentiation J Ethnopharmacol 149 2013 490 498
241. M. Hotta, R. Nakata, M. Katsukawa, K. Hori, S. Takahashi, and H. Inoue Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression J Lipid Res 51 2010 132 139
242. A. Zoechling, F. Liebner, and A. Jungbauer Red wine: a source of potent ligands for peroxisome proliferator-activated receptor gamma Food Funct 2 2011 28 38
243. M. Sato, T. Tai, Y. Nunoura, Y. Yajima, S. Kawashima, and K. Tanaka Dehydrotrametenolic acid induces preadipocyte differentiation and sensitizes animal models of noninsulin-dependent diabetes mellitus to insulin Biol Pharmaceut Bull 25 2002 81 86
244. Y. Isa, Y. Miyakawa, M. Yanagisawa, T. Goto, M.S. Kang, and T. Kawada 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-alpha mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes Biochem Biophys Res Commun 373 2008 429 434
245. A. Jungbauer, and S. Medjakovic Anti-inflammatory properties of culinary herbs and spices that ameliorate the effects of metabolic syndrome Maturitas 71 2012 227 239
246. B.K. Chacko, R.T. Chandler, T.L. D'Alessandro, A. Mundhekar, N.K. Khoo, and N. Botting Anti-inflammatory effects of isoflavones are dependent on flow and human endothelial cell PPARgamma J Nutr 137 2007 351 356
247. M. Mueller, S. Hobiger, and A. Jungbauer Red clover extract: a source for substances that activate peroxisome proliferator-activated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages Menopause 17 2010 379 387
248. S. Kim, H.J. Shin, S.Y. Kim, J.H. Kim, Y.S. Lee, and D.H. Kim Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha Mol Cell Endocrinol 220 2004 51 58
249. O. Mezei, W.J. Banz, R.W. Steger, M.R. Peluso, T.A. Winters, and N. Shay Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells J Nutr 133 2003 1238 1243
250. E. Calleri, G. Pochetti, K.S. Dossou, A. Laghezza, R. Montanari, and D. Capelli Resveratrol and Its Metabolites Bind to PPARs Chembiochem 2014
251. S. Ulrich, S.M. Loitsch, O. Rau, A. von Knethen, B. Brune, and M. Schubert-Zsilavecz Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism Cancer Res 66 2006 7348 7354
252. M. Mueller, V. Beck, and A. Jungbauer PPARalpha activation by culinary herbs and spices Planta Medica 77 2011 497 504
253. S.N. Kim, H.Y. Choi, W. Lee, G.M. Park, W.S. Shin, and Y.K. Kim Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells FEBS Lett 582 2008 3465 3472
254. G. Wolber, and T. Langer LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J Chem Inf Model 45 2005 160 169